Evidence map›Paper›PMID 38074823›Full record

ReviewAmerican journal of translational research2023

Role of microRNA-494 in tumor progression.

Amirhosein Maharati, Iman Akhlaghipour, Negin Taghehchian, Zahra Farshchian Yazdi, Meysam Moghbeli

Open access · greenAbstract readReview
In one paragraph

Review in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Amirhosein MaharatiStudent Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences Mashhad, Iran.
Iman AkhlaghipourStudent Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences Mashhad, Iran.
Negin TaghehchianDepartment of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences Mashhad, Iran.
Zahra Farshchian YazdiDepartment of Medical Genetics, School of Medicine, Shahid Sadoughi University of Medical Sciences Yazd, Iran.
Meysam MoghbeliDepartment of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences Mashhad, Iran.
Mashhad University of Medical Sciences · IRShahid Sadoughi University of Medical Sciences and Health Services · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various progresses in tumor therapy during the recent decades have significantly reduced the cancer related deaths globally. However, there is still a high rate of mortality in these patients. The early stage tumors have no aggressive and clear clinical symptoms in the majority of cancer types, which causes a high rate of therapeutic failure in advanced tumor stages. Therefore, identification of the molecular tumor biology can be promising to introduce the early diagnostic markers. MicroRNAs (miRNAs) are the key regulators of cellular processes that can also be involved in tumor progression as tumor-suppressor or oncogene. Due to the high stability of miRNAs in body fluids, they can be used as the non-invasive diagnostic tumor markers. In the present review, we discussed the role of miR-494 in tumor progression. It has been shown that miR-494 has mainly a tumor suppressor function by regulation of transcriptional and structural factors and signaling pathways such as transforming growth factor-β (TGF-β), WNT, and Janus kinase (JAK)-signal transducer and activator of transcription (STAT). The phosphatase and tensin homolog/phosphoinositide 3-kinase (PTEN/PI3K) axis has been also reported as the main target of miR-494 as an oncogene. These findings suggest that miR-494 is a non-invasive diagnostic marker for the early diagnosis and therapeutic management of cancer patients.

Indexed as

cancerdiagnosismarkerMicroRNA-494non-invasive

Identifiers

PMID38074823
PMCPMC10703645
OpenAlexW4389801419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.